Molecure

Molecure Liabilities

The The Liabilities of Molecure (MOC.WA) as of Oct 27, 2026 is 6.99 M PLN. In the previous year, The Liabilities was 10.31 M PLN — a change of -32.27% (lower).

Liabilities

6.99 MPLN

YoY

-32.27%

Last updated:

In 2025, Molecure's total liabilities amounted to 6.99 M PLN, a -32.27% difference from the 10.31 M PLN total liabilities in the previous year.

The Molecure Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
4.12 M PLN
Jan 1, 2019
6.56 M PLN
Jan 1, 2020
10.09 M PLN
Jan 1, 2021
10.45 M PLN
Jan 1, 2022
11.61 M PLN
Jan 1, 2023
11.34 M PLN
Jan 1, 2024
10.31 M PLN
Jan 1, 2025
6.99 M PLN
The Molecure Liabilities history
YEARLiabilitiesYoY
6.99 MPLN-32.27%
10.31 MPLN-9.09%
11.34 MPLN-2.31%
11.61 MPLN+11.16%
10.45 MPLN+3.49%
10.09 MPLN+53.94%
6.56 MPLN+59.00%
4.12 MPLN-14.91%
4.85 MPLN+93.30%
2.51 MPLN+129.40%
1.09 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Molecure Stock analysis

What does Molecure do? Molecure SA generates revenue through the discovery and development of small molecule therapeutics targeting unmet medical needs, particularly in neoplastic and inflammatory diseases. The company focuses on medicinal chemistry and preclinical biology, leveraging scientific collaborations to advance its drug development pipeline. Its core products include three distinct small molecule programs targeting chitinases hydrolytic enzymes for inflammatory and fibrotic diseases, as well as a program developing small molecule immune modulators to prevent tumor immune escape. The primary buyers of these therapeutics are pharmaceutical companies seeking to acquire or partner on novel drug candidates. The firm operates within the pharmaceutical sector, with its business model centered on drug discovery and development rather than direct commercialization. It relies on partnerships and collaborations to advance its pipeline, particularly in specific disease areas where it enhances its capabilities through scientific alliances. Molecure SA's platform of small molecule programs is designed to address high unmet medical needs, positioning it as a key player in early-stage drug development for inflammatory and fibrotic conditions. Molecure SA's revenue streams are derived from strategic partnerships and potential future licensing agreements for its drug candidates. The company's focus on chitinases hydrolytic enzymes and immune modulators reflects its commitment to addressing complex medical challenges through innovative small molecule solutions. Its business model emphasizes collaboration and scientific expertise to develop therapeutics for diseases with significant treatment gaps. Molecure is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Molecure's Liabilities

Molecure's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Molecure's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Molecure's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Molecure's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Molecure’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Molecure stock

The Liabilities of Molecure is 6.99 M PLN in 2025.

The Liabilities of Molecure changed from 10.31 M PLN to 6.99 M PLN, representing a -32.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Molecure since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Molecure historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Molecure

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Molecure